Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., Samsung Bioepis Co., Ltd., Et Al., decided 29 Jan 25

Regeneron Pharmaceuticals, holding patents for its drug EYLEA®, sued Samsung Bioepis and other companies for patent infringement after they filed applications to market biosimilars. The appeals court upheld the lower court's assertion of personal jurisdiction over Samsung Bioepis, a South Korean company, based on its nationwide marketing plans. The court also found that Regeneron demonstrated a likelihood of success on the merits and irreparable harm if the injunction wasn't granted, thus affirming the preliminary injunction. The court's decision centered on the patentability of Regeneron's claims and Samsung Bioepis's failure to raise substantial questions of invalidity.